Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
作者： M J Keating , H Kantarjian , S O'Brien , C Koller , M Talpaz
关键词:
摘要: Thirty-three patients with chronic lymphocytic leukemia (CLL) advanced Rai stage (III-IV) or progressive (0-II) disease were treated fludarabine as a single agent. Eleven (33%) obtained complete remission (CR), 13 (39%) clinical CR residual nodules the only evidence of (nodular partial [PR]), and two (6%) achieved PR for total response rate 79%. Response was rapid, usually occurring after three to six courses treatment. The major morbidity infection. Febrile episodes occurred in 13% (pneumonia 6%, minor infection 4%, transient fever undocumented cause 3%). Fludarabine appears be most cytoreductive agent so far studied CLL.
manchester.ac.uk参考文章(16)
MJ Keating, H Kantarjian, M Talpaz, J Redman, C Koller, B Barlogie, W Velasquez, W Plunkett, EJ Freireich, KB McCredie, Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood. ,vol. 74, pp. 19- 25 ,(1989) , 10.1182/BLOOD.V74.1.19.19
KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy, BS Pasternack, Clinical staging of chronic lymphocytic leukemia. Blood. ,vol. 46, pp. 219- 234 ,(1975) , 10.1182/BLOOD.V46.2.219.219
B L Meserve, I Royston, S M Baird, J A Majda, J C Griffiths, Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. Journal of Immunology. ,vol. 125, pp. 725- 731 ,(1980)
Donald W. Kufe, Edward Stopa, David R. Spriggs, Robert J. Mayer, William Schoene, Fludarabine Phosphate (NSC 312878) Infusions for the Treatment of Acute Leukemia: Phase I and Neuropathological Study Cancer Research. ,vol. 46, pp. 5953- 5958 ,(1986)
A Sawitsky, KR Rai, O Glidewell, RT Silver, Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. ,vol. 50, pp. 1049- 1059 ,(1977) , 10.1182/BLOOD.V50.6.1049.1049
R P Warrell, E Berman, Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. Journal of Clinical Oncology. ,vol. 4, pp. 74- 79 ,(1986) , 10.1200/JCO.1986.4.1.74
J. L. Binet, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, P. Colona, F. Oberling, M. Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. T. Duault, M. Monconduit, S. Belabbes, F. Gremy, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer. ,vol. 48, pp. 198- 206 ,(1981) , 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V
Bruce D. Cheson, John M. Bennett, Kanti R. Rai, Michael R. Grever, Neil E. Kay, Charles A. Schiffer, Martin M. Oken, Michael J. Keating, David H. Boldt, Sanford J. Kempin, Kenneth A. Foon, Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group American Journal of Hematology. ,vol. 29, pp. 152- 163 ,(1988) , 10.1002/AJH.2830290307
Ediz Z. Ezdinli, Leon Stutzman, C. William Aungst, Dincer Firat, Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia Cancer. ,vol. 23, pp. 900- 909 ,(1969) , 10.1002/1097-0142(196904)23:4<900::AID-CNCR2820230427>3.0.CO;2-4
K. Ideström, E. Kimby, M. Björkholm, H. Mellstedt, L. Engstedt, G. Gahrton, B. Johansson, D. Killander, K.-H. Robérts, A.-M. Stalfelt, A.-M. Udén, B. Wadman, S. Wählby, Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone. European Journal of Cancer and Clinical Oncology. ,vol. 18, pp. 1117- 1123 ,(1982) , 10.1016/0277-5379(82)90092-X